Concepts (67)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fish Oils | 1 | 2019 | 21 | 0.660 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2019 | 12 | 0.660 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 186 | 0.590 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 514 | 0.500 |
Why?
|
| Blood Component Removal | 2 | 2022 | 19 | 0.400 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2022 | 43 | 0.390 |
Why?
|
| Nephrotic Syndrome | 2 | 2022 | 61 | 0.380 |
Why?
|
| Kidney Transplantation | 2 | 2022 | 839 | 0.200 |
Why?
|
| Kidney Diseases | 1 | 2021 | 307 | 0.160 |
Why?
|
| Aftercare | 1 | 2018 | 114 | 0.140 |
Why?
|
| Child | 4 | 2022 | 6405 | 0.140 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1140 | 0.130 |
Why?
|
| Acetaminophen | 1 | 2016 | 111 | 0.130 |
Why?
|
| Cisplatin | 1 | 2016 | 192 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2018 | 458 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 504 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 232 | 0.110 |
Why?
|
| Kidney | 1 | 2018 | 945 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2016 | 447 | 0.090 |
Why?
|
| Amidines | 1 | 2010 | 7 | 0.090 |
Why?
|
| Drug Design | 1 | 2010 | 107 | 0.080 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2010 | 201 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 659 | 0.070 |
Why?
|
| Humans | 6 | 2022 | 68618 | 0.060 |
Why?
|
| Sclerosis | 1 | 2021 | 32 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 243 | 0.050 |
Why?
|
| Remission Induction | 1 | 2021 | 111 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2021 | 223 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 343 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 948 | 0.040 |
Why?
|
| Male | 4 | 2022 | 37321 | 0.040 |
Why?
|
| Urinalysis | 1 | 2016 | 27 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 202 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 540 | 0.030 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2016 | 81 | 0.030 |
Why?
|
| Drug Overdose | 1 | 2016 | 67 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 431 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1054 | 0.030 |
Why?
|
| Female | 3 | 2021 | 38074 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1745 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2455 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 2891 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3259 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 3187 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2673 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 1593 | 0.020 |
Why?
|
| Oxadiazoles | 1 | 2010 | 7 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 234 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2279 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 322 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 420 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 144 | 0.020 |
Why?
|
| Sphingosine | 1 | 2010 | 315 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 4655 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 7277 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7367 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1174 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 8912 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5717 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 5300 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 21147 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 8474 | 0.010 |
Why?
|
| Adult | 1 | 2016 | 21403 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 20881 | 0.010 |
Why?
|